One of the most widely seen names in the health care sector HIMS & Her Health Inc. NYSE: HIMSNot only because of its primary work over the past six months, but also because of the basic growth story, which makes it feel like a miracle in making it. The reason behind his popularity is the fact that it combines the safety of health services as well as the type of growth for the technological space of the market.
Hims & her health today
Hims & Rels Health
As of 03:59 pm
- 52 weeks
- 13.47 dollars
▼
72.98 dollars
- P/E ratio.
- 90.68
- The target price
- $ 39.83
However, most investors have linked Hims & Hers with a recent weight loss world, in a type of OzemPic mutation. Given the company recently entering this field, this bond has some justification.
However, these assumptions ignore the fact that the company was already on the path of success and double growth before making this decision.
The risks are especially high, along with uncertainty, and now after he contributed Novo Nordsk NYSE: NVO It decreased by up to 31 % during the past month alone. The declining reaction was operated through organizational intervention and investigations into weight loss products, which specifically targeted Novo Nordisk due to its excessive concentration in the product and limited diversification.
Will House and her and her with Novo be connected?
Because of the connection systems, Hims & HERS shares may also suffer from a slight stagnation. However, the basics dictate that the decline should not be harsh as it was for Novo Nordisk. By displaying a varied product and a completely different business model, that is why Hims & Hers may make it good.
HIMS & HERS reinforces the world of health care in a way that novo Nordisk cannot, this means that work as a distant platform indicates the best way investors tend to search for in every work: subscriptions. because More than 90 % of the company’s revenues come through subscriptionsHe may stick to shaking and stronger than expected.
This is because the contributions enable investors and Wall Street analysts to predict more precisely accurately in any business field in any work, as the rate of installation tends to be much less, especially in health care services. Keep this in mind, the fact that the Hims & Hers shares are still trading by 95 % of 52 weeks. A strong sign that optimism is still alive.
On the other hand, Novo Nordsk fell to 35 % of its highest level in 52 weeks, as investors show the market awareness that Hims & Hers are not exposed to weight loss products such as Novo Nordisk today. The possibility of this momentum will continue in the future, and evidence can be found in the company’s basics.
All red indicators are hot for him
Investors examine it The latest quarterly results We will not see any reason for the arrow’s decline in the near future, although some concerns about exposure to weight loss products. Revenue increased 111 % during the past yearThis clearly indicates the strong demand for this innovative health platform. The main driver of this growth is the rapid and aggressive adoption rate and the constant expansion of the market share that the company’s reports constantly.
HIMS & HERS Health Stock Expectations today
$ 39.83
-36.85 % is the downsideReduce
Based on 13 analyst classifications
| The current price | $ 63.08 |
|---|---|
| High expectations | $ 68.00 |
| Average expectations | $ 39.83 |
| Low expectations | $ 26.00 |
HIMS & HERS Health Desicite Defelds
The subscribers grew to 2.4 million, an increase of 38 % compared to the same quarter last year. This is not just a slight increase in prices for each subscription but also attractive growth at the company’s user base, which is the main engine in any company or company that relies on subscription.
Another factor that investors need to be in mind is that Hims & Hers Management has repeated the general financial guidance for the year 2025. This is a strong point, given that other companies have chosen not to provide guidance due to the current commercial tariffs and the uncertainty in inflation in the economy.
One of the benefits that has a predictable and stable business model because this is that it provides certainty in the market as every investor needs it. Finally, this financial growth has decreased to one of the most important measures: free cash flow (working cash flow minus capital expenses).
Free cash flow It was reported to up to 50.1 million dollars for this quarter, which rose nearly five times compared to $ 11.9 million in the same quarter of last year. This scale is concerned because it represents the most compound capabilities, as a free cash flow is usually used to re -invest to pay more growth.
It seems that all the evidence, both technical momentum and basic growth, indicate very low opportunities to shake and retreat with Novo Nordisk, and this is one of the condemnation that investors can take this name to move forward.
Before you think about his health and health, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … Hims & HERS Health was not in the list.
While Hims & HERS Health currently has a decrease between analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
I wonder where to start (or end) with artificial intelligence shares? These ten simple stocks can help investors build a long -term wealth as artificial intelligence continues to grow to the future.
